What is the target of Imatinib?

The main target of Imatinib (Imatinib) is a specific type of tyrosine kinase enzymes (tyrosine kinase enzymes), which play an important role in cell signaling and growth regulation. The targets of imatinib include the following two main proteins:

1.BCR-ABLfusion protein:BCR-ABLfusion protein is one of the most important targets of imatinib. This protein is produced by abnormal chromosomal fusions in patients with chronic myelogenous leukemia (CML) and has abnormal tyrosine kinase activity. BCR-ABLThe abnormal activity of fusion protein leads to abnormal proliferation of white blood cells and is the main pathogenic factor of CML. Imatinib blocks the abnormal proliferation of white blood cells by inhibiting the kinase activity of the BCR-ABL fusion protein, thus effectively treating CML.

2.KITTyrosine kinase: KITTyrosine kinase is another important target of imatinib, especially in the treatment of cortical renal cancer (Gastrointestinal Stromal Tumor, GIST). In GIST patients, KITtyrosine kinase often exhibits abnormal activity, leading to tumor growth. Imatinib slows the development of GIST by inhibiting the activity of KIT tyrosine kinase.

Imatinib was launched in China as early as 2003. The domestic medical insurance price is about 700 yuan, and the specification is 100mg*60. Due to the large differences in medical insurance in different places, please consult the local pharmacy or medical insurance bureau for specific prices. Foreign medicines are divided into original drugs and generic drugs. Original drugs are mainly Turkish original drugs, and the price is relatively high, about 3300 yuan; generic drugs are mainly Indian generic drugs, and the specifications of Indian generic drugs100mg*120The price is about a few hundred yuan, which is much cheaper than in China. The ingredients of foreign original drugs and generic drugs are basically the same as those of domestic imatinib.